Skip to main navigation

Skip to content

Careers
Contact Us
中文

Home
About
Research & Development
Therapies
Newsroom
Investors

Careers
Contact Us
中文

Press Releases

Overview
Press Releases
Events and Presentations
- Annual General Meeting
Corporate Governance
Stock Information
Financials
- SEC Filings
- Earnings Releases
Resources
- Email Alerts
- Contact IR

Year

Aug 09, 2024

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

Aug 08, 2024

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

Jul 26, 2024

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

Jul 10, 2024

Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results

Jul 02, 2024

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

Jun 03, 2024

Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA

May 29, 2024

Legend Biotech to Participate in the Jefferies Global Healthcare Conference

May 23, 2024

Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

May 13, 2024

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

Apr 22, 2024

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 29

GLOBAL HEADQUARTERS

2101 COTTONTAIL LANE

SOMERSET, NJ 08873, USA

+1-732-317-5050

Footer Links

ABOUT US
RESEARCH & DEVELOPMENT
THERAPIES
NEWSROOM
CAREERS
ETHICS & COMPLIANCE
COMPLIANCE HOTLINE
INVESTORS
COOKIE POLICY
PRIVACY POLICY
LEGAL NOTICE
CONTACT US
SITE MAP

© 2024 Legend Biotech. All rights reserved. dedication

You are about to leave Investors.LegendBiotech.com